Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643804 | 0.89 | MEN1 (0.51) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL30296312 | 0.89 | MEN1 (0.51) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL26095977 | 0.89 | KDM4E (0.51) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL30296402 | 0.89 | KDM4E (0.51) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL2643388 | 0.88 | MAPT (0.55) | KDM4EMAPTMEN1KMT2ATP53 | |
| SCHEMBL2643348 | 0.85 | KDM4E (0.54) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL2643782 | 0.83 | KDM4E (0.52) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL2644601 | 0.83 | KDM4E (0.51) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL30296358 | 0.83 | KDM4E (0.45) | KDM4EHKDC1FFAR1MAPTMAPK1 | |
| SCHEMBL2643718 | 0.83 | MEN1 (0.49) | KDM4EHKDC1FFAR1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-11-07 | — | — | US | disclosed |
| EP-4419203-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2024-08-28 | — | — | EP | disclosed |
| WO-2023067322-A1 | TRICYCLIC GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2023-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368173-A1 | TRICYCLIC GPR65 MODULATORS | GPR65, GPR3, NR1H2 | KDM4E 3978/4885HKDC1 1659/4885FFAR1 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.